News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalex, Inc. (PRTX) Announces Interim Findings From U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients


2/10/2014 8:10:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced preliminary findings from a limited interim analysis of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The interim analysis included patients in the first four dosing cohorts of the five-cohort study through day 85 of the study protocol.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES